Aarhus University Seal / Aarhus Universitets segl

Isa Niemann

Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer – A nationwide study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Ligita Paskeviciute Froeding, Rigshospitalet
  • ,
  • Claus Høgdall, Rigshospitalet
  • ,
  • Elisabeth Kristensen, Rigshospitalet
  • ,
  • Vibeke Zobbe, Rigshospitalet
  • ,
  • Isa Niemann
  • Gitte Ørtoft, Rigshospitalet
  • ,
  • Ingrid Thranov, Rigshospitalet
  • ,
  • Ole Mathiesen
  • ,
  • Jann Mortensen, Rigshospitalet
  • ,
  • Tine Henrichsen Schnack, Rigshospitalet

Objective: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients. Methods: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included. Results: The SN-procedure was performed in 286 patients, of these 190 (66.4%) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1%) had one or more recurrences during a median follow-up of 30 months (range 1–83). Four patients (2.1%) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4%) experienced a local recurrence in vulva, 1 patient (0.5%) had a recurrence in the vulva and the groin and 4 patients (2.1%) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84% and 93%, respectively. The 3-year OS for patients with recurrent disease was 58%. Conclusions: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.

TidsskriftGynecologic Oncology
Sider (fra-til)124-130
Antal sider7
StatusUdgivet - jan. 2020

Se relationer på Aarhus Universitet Citationsformater

ID: 185886936